Analysis of 2nd line panitumumab + FOLFIRI efficacy in wild type RAS converted subjects from initially mutated RAS subjects with metastatic colorectal cancer treated in 1st line with standard FOLFOX + bevacizumab treatment
Latest Information Update: 09 Apr 2021
Price :
$35 *
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colon cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms CONVERTIX
- 09 Apr 2021 Status changed from recruiting to discontinued.
- 23 Mar 2018 New trial record